Pathogenesis-oriented therapy of psoriasis using biologics
- 20 July 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 22 (12) , 1463-1473
Abstract
Psoriasis is currently regarded an immune-mediated inflammatory disease. The central pathogenic axis comprises interleukin-23, TH17-lymphocytes differentiating under its influence, and interleukin-...Keywords
This publication has 98 references indexed in Scilit:
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialThe Lancet, 2013
- The interleukin-17 cytokine family: critical players in host defence and inflammatory diseasesImmunology, 2011
- The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidityExperimental Dermatology, 2011
- Effective continuous systemic therapy of severe plaque‐type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational studyJournal of the European Academy of Dermatology and Venereology, 2011
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptideNature, 2007
- IL-25 regulates Th17 function in autoimmune inflammationJournal of Experimental Medicine, 2007
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003
- Interleukin-12 and the regulation of innate resistance and adaptive immunityNature Reviews Immunology, 2003
- Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced MacrophagesScience, 1993